2008
DOI: 10.1200/jco.2008.26.15_suppl.19541
|View full text |Cite
|
Sign up to set email alerts
|

An exploratory feasibility study examining the addition of arsenic trioxide (ATO) and ascorbic acid (AA) to bortezomib, thalidomide, and dexamethasone (VTD) in the treatment of relapsed and refractory multiple myeloma

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles